Securities Code: 300255 Securities Abbreviation: Changshan Pharmaceutical Announcement No.: 2026-12
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Resolution Announcement of the Seventh Meeting of the Sixth Board of Directors
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from false records, misleading statements, or major omissions.
I. Convening of the Board Meeting
The seventh meeting of the sixth Board of Directors of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was held in the conference room of the Company's office building on April 28, 2026, in person. The notice of this meeting was sent to each director by email or direct delivery on April 18, 2026, ensuring that each director received the notice. The directors attending the meeting were fully aware of the necessary information related to the matters to be discussed. A total of 6 directors were eligible to vote, and 6 directors actually voted. This meeting was presided over by Mr. Gao Xiaodong, Chairman of the Company, in accordance with the "Company Law" and the "Articles of Association."
II. Matters Considered at the Board Meeting
The meeting voted on the following proposals by signed ballot:
- Proposal on the <2025 Annual Work Report of the Board of Directors> was approved. The directors of the Company summarized their performance and related work in 2025 and compiled the <2025 Annual Work Report of the Board of Directors>. In 2025, the Board of Directors strictly followed the requirements of laws and regulations such as the "Company Law" and the "Securities Law," normative documents, and the "Articles of Association" and the "Rules of Procedure for Board Meetings" to diligently perform its duties entrusted by the shareholders' meeting, conscientiously carry out various tasks, and promote the development of the Company. Independent Directors Mr. Cao Deying and Mr. Wang Xiangjun submitted their <Independent Directors' 2025 Annual Performance Reports> to the Board, and will present their reports at the Company's 2025 Annual Shareholders' Meeting. For the details of the performance reports, please refer to the <Independent Directors' 2025 Annual Performance Reports> released by the Company on the same day. Voting results: 6 votes in favor; 0 votes against; 0 abstentions.
This proposal needs to be submitted to the shareholders' meeting for consideration.
-
Proposal on the <2025 Annual Work Report of the General Manager> was approved. The Board of Directors listened to the <2025 Annual Work Report of the General Manager> made by General Manager Mr. Gao Xiaodong, and believes that this report objectively and truthfully reflects the Company's work and achievements in implementing the resolutions of the Board of Directors, business operations management, and the implementation of various company systems in 2025. Voting results: 6 votes in favor; 0 votes against; 0 abstentions.
-
Proposal on the <2025 Annual Report and its Summary> was approved. The Company's <2025 Annual Report> and <2025 Annual Report Summary> were prepared in accordance with relevant laws, regulations, and normative documents. The content of the report truthfully, accurately, and completely reflects the Company's operating conditions in 2025, and contains no false records, misleading statements, or major omissions. For specific content, please refer to the <2025 Annual Report> and <2025 Annual Report Summary> released by the Company on the same day. The financial report in the Company's <2025 Annual Report> has been reviewed and approved by the Company's Board of Directors' Audit Committee. Voting results: 6 votes in favor; 0 votes against; 0 abstentions. This proposal needs to be submitted to the shareholders' meeting for consideration.